Journal article

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik, Jens Kuhle



BACKGROUND: The added value of neurofilament light chain levels in serum (sNfL) to the concept of no evidence of disease activity-3 (NEDA-3) has not yet been investigated in detail. OBJECTIVE: To assess whether combination of sNfL with NEDA-3 status improves identification of patients at higher risk of disease activity during the following year. METHODS: We analyzed 369 blood samples from 155 early relapsing-remitting MS patients on interferon beta-1a. We compared disease activity, including the rate of brain volume loss in subgroups defined by NEDA-3 status and high or low sNfL (> 90th or < 90th percentile). RESULTS: In patients with disease activity (EDA-3), those with higher sNFL had high..

View full abstract


Awarded by Czech Ministry of Education

Awarded by Czech Ministry of Health

Awarded by AZV grant

Awarded by Sanofi

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Czech Ministry of Education (project Progres Q27/LF1), the Czech Ministry of Health (project RVO-VFN64165) and the AZV grant NV 18-04-00168. SET study was supported by Biogen. Statistical analysis was supported by Sanofi (GZ-2017-11718).